Institutional members access full text with Ovid®

Share this article on:

Raloxifene improves the ovariectomy-induced impairment in endothelium-dependent vasodilation

Takahashi, Kazuhiro MD, PhD1; Mori-Abe, Akiko MD, PhD1; Takata, Keiko MD1; Ohta, Tsuyoshi MD1; Kawagoe, Jun MD, PhD1; Tsutsumi, Seiji MD, PhD1; Ohmichi, Masahide MD, PhD2; Kurachi, Hirohisa MD, PhD1

doi: 10.1097/01.gme.0000248704.30204.33
Articles

Objective: To examine the effect of raloxifene on the endothelial dysfunction caused by surgical menopause.

Design: Ten premenopausal women who underwent gynecological surgery with ovariectomy were divided into two groups. Five participants used raloxifene (60 mg/d) for 7 days staring 1 week after the surgery, and the other five participants did not use raloxifene. We examined the changes in flow-mediated dilatation (FMD) of the brachial artery using ultrasonography. Vasodilation in response to nitroglycerin was also studied. We also measured the brachial-ankle pulse wave velocity to examine the change in arterial stiffness in these participants before and after surgical menopause.

Results: In both the raloxifene and control groups, a significant decrease in FMD was observed 1 week after the surgery. Although no further changes in FMD were observed in the control group at 2 weeks after surgery, FMD was significantly increased in the raloxifene group. No remarkable changes in nitroglycerin or brachial-ankle pulse wave velocity were observed after surgery in either group.

Conclusions: Raloxifene rapidly restored FMD that was impaired after surgical menopause. Therefore, raloxifene may be effective for ameliorating and maintaining endothelial function in premenopausal women who undergo ovariectomy.

Raloxifene rapidly restored the flow-mediated dilatation which was impaired after surgical menopause. Raloxifene may be effective for ameliorating and maintaining the endothelial function in premenopausal women who undergo ovariectomy.

From the 1Department of Obstetrics and Gynecology, Yamagata University School of Medicine, Iidanishi, Yamagata, Japan; and 2Department of Obstetrics and Gynecology, Osaka Medical College, Daigakumachi, Takatsuki, Osaka, Japan.

Received May 17, 2006; revised and accepted October 4, 2006.

Funding/support: This work was supported in part by grants-in-aid for scientific research 18591822 (to K.T.) and 17390445 (to H.K.) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan and in part by grants-in-aid for the 21st Century Center of Excellence Program from the Japan Society for the Promotion of Science.

Financial disclosure: None reported.

Address correspondence to: Kazuhiro Takahashi, MD, PhD, Department of Obstetrics and Gynecology, Yamagata University School of Medicine, 2-2-2, Iidanishi, Yamagata, Yamagata, 990-9585, Japan. E-mail: ktaka@med.id.yamagata-u.ac.jp.

©2007The North American Menopause Society